nach oben

Erschienen in:

05.02.2021 | Original Paper

The Role of Increased Connective Tissue Growth Factor in the Pathogenesis of Oral Submucous Fibrosis and its Malignant Transformation—An Immunohistochemical Study

verfasst von: Aakruti Mahendra Shah, Kejal Jain, Rajiv S. Desai, Shivani Bansal, Pankaj Shirsat, Pooja Prasad, Kshitija Bodhankar

Erschienen in: Head and Neck Pathology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Connective tissue growth factor (CTGF), a matricellular protein of the CCN family of extracellular matrix-associated heparin-binding proteins, is highly expressed in various organ fibrosis and several malignant tumors. Although a few studies have been conducted using CTGF in oral submucous fibrosis (OSF) and oral squamous cell carcinoma, no study has demonstrated its relation with various stages of OSF and its malignant transformation. The present study investigated the possible role of CTGF in the pathogenesis of OSF and its malignant transformation by using immunohistochemistry. Ten formalin-fixed paraffin-embedded tissue blocks, each of Stage 1 OSF, Stage 2 OSF, Stage 3 OSF, Stage 4 OSF, well- differentiated squamous cell carcinoma (WDSCC) with OSF and WDSCC without OSF were stained for CTGF by immunohistochemistry. Ten cases of healthy buccal mucosa (NOM) were included as controls. The present study demonstrated a statistically significant expression of CTGF in the epithelium and connective tissue of OSF and WDSCC with and without OSF cases against its complete absence in NOM. We observed an upregulation of CTGF expression from NOM to various stages of OSF to WDSCC with or without OSF. A gradual upregulation of the CTGF expression in various stages of OSF to WDSCC (with and without OSF) against its complete absence in NOM suggests that CTGF plays an important role in the pathogenesis of OSF and its malignant transformation.

Ekanayaka RP, Tilakaratne WM. Oral submucous fibrosis: review on mechanisms of malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(2):192–9.PubMedCrossRef

Tilakratne WM, Eknayaka RP, Warnakulasuriya S. Oral submucous fibrosis: a historical perspective and a review on etiology and pathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(2):178–91.CrossRef

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Betel-quid and areca-nut chewing and some areca-nut derived nitrosamines. IARC Monogr Eval Carcinog Risks Hum. 2004;85:1.PubMedCentral

Khan I, Agarwal P, Thangjam GS, Radhesh R, Rao SG, Kondaiah P. Role of TGF beta and BMP 7 in the pathogenesis of oral submucous fibrosis. Growth Factors. 2011;29:119–27.PubMedCrossRef

Haque MF, Harris M, Meghji S, Barrett AW. Immunolocalization of cytokines and growth factors in oral submucous fibrosis. Cytokine. 1998;10(9):713–9.PubMedCrossRef

Illeperuma RP, Ryu MH, Kim KY, Tilakaratne WM, Kim J. Relationship of fibrosis and the expression of TGF-β1, MMP‐1, and TIMP‐1 with epithelial dysplasia in oral submucous fibrosis. Oral Med Pathol. 2010;15(1):21–8.CrossRef

Khan I, Kumar N, Pant I, Narra S, Kondaiah P. Activation of TGF-β pathway by areca nut constituents: a possible cause of oral submucous fibrosis. PLoS ONE. 2012;7(12):e51806.PubMedPubMedCentralCrossRef

Kale AD, Mane DR, Shukla D. Expression of transforming growth factor β and its correlation with lipodystrophy in oral submucous fibrosis: an immunohistochemical study. Med Oral Patol Oral Cir Bucal. 2013;18(1):e12-8.PubMedCrossRef

Kamath VV, Satelur KP, Rajkumar K, Krishnamurthy S. Transforming growth factor beta 1 in oral submucous fibrosis: an immunohistochemical study-understanding the pathogenesis. J Dent Res Rev. 2014;1(2):75–80.CrossRef

10.

Kumar V, Suma S, Kumar BV, Yanduri S, Shyamala K. Correlation between transforming growth factor-beta expression and mast cell count in different grades of oral submucous fibrosis. J Adv Clin Res Insights. 2016;3(4):123–8.CrossRef

11.

Grotendorst GR. Connective tissue growth factor: a mediator of TGF- β action on fibroblasts. Cytokine Growth Factor Rev. 1997;8(3):171–9.PubMedCrossRef

12.

Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, Takigawa M, Nakanishi T, Takehara K. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: a mouse fibrosis model. J Cell Physiol. 1999;181(1):153–9.PubMedCrossRef

13.

Sharma M, Radhakrishnan R. CTGF is obligatory for TGF-β1 mediated fibrosis in OSMF. Oral Oncol. 2016;56:e10-1.PubMedCrossRef

14.

Lau LF, Lam ST. The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res. 1999;248(1):44–57.PubMedCrossRef

15.

Leask A. Trial by CCN2: a standardized test for fibroproliferative disease? J Cell Commun Signal. 2009;3:87–8.PubMedPubMedCentralCrossRef

16.

Jun JI, Lau LF. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov. 2011;10(12):945–63.PubMedPubMedCentralCrossRef

17.

Lee CH, Shah B, Moioli EK, Mao JJ. CTGF directs fibroblast differentiation from human mesenchymal stem/stromal cells and defines connective tissue healing in a rodent injury model. J Clin Invest. 2010;120(9):3340–9.PubMedPubMedCentralCrossRef

18.

Leask A, Sa S, Holmes A, Shiwen X, Black CM, Abraham DJ. The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol Pathol. 2001;54(3):180–3.PubMedPubMedCentralCrossRef

19.

Allen JT, Knight RA, Bloor CA, Spiteri MA. Enhanced insulin-like growth factor binding protein-related protein 2 (connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol. 1999;21(6):693–700.PubMedCrossRef

20.

Paradis V, Dargere D, Vidaud M, De Gouville AC, Huet S, Martinez V, Gauthier JM, Ba N, Sobesky R, Ratziu V, Bedossa P. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology. 1999;30(4):968–76.PubMedCrossRef

21.

Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, Goldschmeding R. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 1998;53(4):853–61.PubMedCrossRef

22.

Kantarci A, Black S, Xydas C, Murawel P, Uchida Y, Yucekal-Tuncer B, Atilla G, Emingil G, Uzel MI, Lee A, Firatli E, Sheff M, Hasturk H, Van Dyke TE, Trackman PC. Epithelial and connective tissue cell CTGF/CCN2 expression in gingival fibrosis. J Pathol. 2006;210(1):59–66.PubMedPubMedCentralCrossRef

23.

Deng YT, Chen HM, Cheng SJ, Chiang CP, Kuo MY. Arecoline-stimulated connective tissue growth factor production in human buccal mucosal fibroblasts: modulation by curcumin. Oral Oncol. 2009;45(9):e99−105.PubMedCrossRef

24.

Chu CY, Chang CC, Prakash E, Kuo ML. Connective tissue growth factor (CTGF) and cancer progression. J Biomed Sci. 2008;15(6):675–85.PubMedCrossRef

25.

Moritani NH, Kubota S, Nishida T, Kawaki H, Kondo S, Sugahara T, Takigawa M. Suppressive effect of overexpressed connective tissue growth factor on tumor cell growth in a human oral squamous cell carcinoma-derived cell line. Cancer Lett. 2003;192(2):205–14.PubMedCrossRef

26.

Yang MH, Lin BR, Chang CH, Chen ST, Lin SK, Kuo MY, Jeng YM, Kuo ML, Chang CC. Connective tissue growth factor modulates oral squamous cell carcinoma invasion by activating a miR-504/FOXP1 signalling. Oncogene. 2012;31(19):2401–11.PubMedCrossRef

27.

Lai WT, Li YJ, Wu SB, Yang CN, Wu TS, Wei YH, Deng YT. Connective tissue growth factor decreases mitochondrial metabolism through ubiquitin-mediated degradation of mitochondrial transcription factor A in oral squamous cell carcinoma. J Formos Med Assoc. 2018;117(3):212–9.PubMedCrossRef

28.

Otte A, Maier-Lenz H, Dierckx RA. Good clinical practice: historical background and key aspects. Nucl Med Commun. 2005;26(7):563–74.PubMedCrossRef

29.

Lai DR, Chen HR, Lin LM, Huang YL, Tsai CC, Lai DR. Clinical evaluation of different treatment methods for oral submucous fibrosis: a 10-year experience with 150 cases. J Oral Pathol Med. 1995;24(9):402–6.PubMedCrossRef

30.

Anneroth G, Batsakis J, Luna M. Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas. Scand J Dent Res. 1987;95(3):229–49.PubMed

31.

Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res. 1990;50(21):7057–61.PubMed

32.

Yanjia H, Xinchun J. The role of epithelial–mesenchymal transition in oral squamous cell carcinoma and oral submucous fibrosis. Clin Chim Acta. 2007;383(1–2):51–6.PubMedCrossRef

33.

Ekanayaka RP, Tilakaratne WM. Oral submucous fibrosis: review on mechanisms of pathogenesis and malignant transformation. J Carcinog Mutagen. 2013;S5:002.

34.

Mullis TC, Tang X, Chong KT. Expression of connective tissue growth factor (CTGF/CCN2) in head and neck squamous cell carcinoma. J Clin Pathol. 2008;61(5):606–10.PubMedCrossRef

35.

Kikuchi R, Kikuchi Y, Tsuda H, Maekawa H, Kozaki K, Imoto I, Tamai S, Shiotani A, Iwaya K, Sakamoto M, Sekiya T, Matsubara O. Expression and clinical significance of connective tissue growth factor in advanced head and neck squamous cell cancer. Hum Cell. 2014;27(3):121–8.PubMedCrossRef

36.

Wu YL, Li HY, Zhao XP, Jiao JY, Tang DX, Yan LJ, Wan Q, Pan CB. Mesenchymal stem cell derived CCN2 promotes the proliferation, migration and invasion of human tongue squamous cell carcinoma cells. Cancer Sci. 2017;108(5):897–909.PubMedPubMedCentralCrossRef

37.

Chang JZ, Yang WH, Deng YT, Chen HM, Kuo MY. Thrombin stimulated connective tissue growth factor (CTGF/CCN2) production in human buccal mucosal fibroblasts: inhibition by epigallocatechin-3-gallate. Head Neck. 2012;34(8):1089–94.PubMedCrossRef

38.

Patil AA, Bhavthankar JD, Barpande SR, Mandale MS. Estimation of serum connective tissue growth factor in oral submucous fibrosis patients and its clinico-pathologic correlation. J Int Oral Health. 2015;7(11):84–90.

39.

Gottipamula S, Sundarrajan S, Moorthy A, Padmanabhan S, Sridhar N. Buccal mucosal epithelial cells downregulate CTGF expression in buccal submucosal fibrosis fibroblasts. J Maxillofac Oral Surg. 2018;17(2):254–9.PubMedCrossRef

40.

Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199–210.PubMedPubMedCentralCrossRef

41.

Derrick T, Luthert PJ, Jama H, Hu VH, Massae P, Essex D, Holland MJ, Burton MJ. Increased epithelial expression of CTGF and S100A7 with elevated subepithelial expression of IL-1β in trachomatous trichiasis. PLoS Negl Trop Dis. 2016;10(6):e0004752.PubMedPubMedCentralCrossRef

42.

Kondaiah P, Pant I, Khan I. Molecular pathways regulated by areca nut in the etiopathogenesis of oral submucous fibrosis. Periodontol 2000. 2019;80(1):213–24.PubMedCrossRef

43.

Sonnylal S, Xu S, Jones H, Tam A, Sreeram VR, Ponticos M, Norman J, Agarwal P, Abraham D, deCrombrugghe B. Connective tissue growth factor causes EMT-like cell fate changes in vivo and in vitro. J Cell Sci. 2013;126(Pt 10):2164–75.PubMedPubMedCentral

44.

Tsai CC, Ma RH, Shieh TY. Deficiency in collagen and fibronectin phagocytosis by human buccal mucosa fibroblasts in vitro as a possible mechanism for oral submucous fibrosis. J Oral Pathol Med. 1999;28(2):59–63.PubMedCrossRef

45.

Risau W. Mechanisms of angiogenesis. Nature. 1997;386(6626):671–4.PubMedCrossRef

46.

Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9(6):653–60.PubMedCrossRef

47.

Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6(4):389–95.PubMedCrossRef

48.

Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1–18.PubMedCrossRef

49.

Van der Veer WM, Niessen FB, Ferreira JA, Zwiers PJ, de Jong EH, Middelkoop E, Molema G. Time course of the angiogenic response during normotrophic and hypertrophic scar formation in humans. Wound Repair Regen. 2011;19(3):292–301.PubMedCrossRef

50.

Bradham DM, Igarshi A, Potter RL, Grotendorst GR. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol. 1991;114(6):1285–94.PubMedCrossRef

51.

Babic AM, Chen CC, Lau LF. Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol. 1999;19(4):2958–66.PubMedCrossRef

52.

Kubota S, Takigawa M. CCN family proteins and angiogenesis: from embryo to adulthood. Angiogenesis. 2007;10(1):1–11.PubMedCrossRef

53.

Desai RS, Mamatha GS, Khatri MJ, Shetty SJ. Immunohistochemical expression of CD34 for characterization and quantification of mucosal vasculature and its probable role in malignant transformation of atrophic epithelium in oral submucous fibrosis. Oral Oncol. 2010;46(7):553–8.PubMedCrossRef

54.

Sharada P, Swaminathan U, Nagamalini BR, Kumar KV, Ashwini BK, Lavanya VL. Coalition of E-cadherin and vascular endothelial growth factor expression in predicting malignant transformation in common oral potentially malignant disorders. J Oral Maxillofac Pathol. 2018;22(1):40.PubMedPubMedCentral

55.

Sharma E, Tyagi N, Gupta V, Narwal A, Vij H, Lakhnotra D. Role of angiogenesis in oral submucous fibrosis using vascular endothelial growth factor and CD34: an immunohistochemical study. Indian J Dent Res. 2019;30(5):755–62.PubMedCrossRef

56.

Binnie WH, Cawson RA. A new ultrastructural finding in oral submucous fibrosis. Br J Dermatol. 1972;86(3):286–90.PubMedCrossRef

57.

El-Labban NG, Canniff JP. Ultrastructural findings of muscle degeneration in oral submucous fibrosis. J Oral Pathol Med. 1985;14(9):709–17.CrossRef

58.

Rooban T, Saraswathi TR, Al Zainab FH, Devi U, Eligabeth J, Ranganathan K. A light microscopic study of fibrosis involving muscle in oral submucous fibrosis. Indian J Dent Res. 2005;16(4):131–4.PubMedCrossRef

59.

Sumathi MK, Balaji N, Malathi N. A prospective transmission electron microscopic study of muscle status in oral submucous fibrosis along with retrospective analysis of 80 cases of oral submucous fibrosis. J Oral Maxillofac Pathol. 2012;16(3):318–24.PubMedPubMedCentralCrossRef

60.

Chawla H, Urs AB, Augustine J, Kumar P. Characterization of muscle alteration in oral submucous fibrosis-seeking new evidence. Med Oral Patol Oral Cir Bucal. 2015;20(6):e670-7.PubMedPubMedCentralCrossRef

61.

Liu F, Tang W, Chen D, Li M, Gao Y, Zheng H, Chen S. Expression of TGF-β1 and CTGF is associated with fibrosis of denervated sternocleidomastoid muscles in mice. Tohoku J Exp Med. 2016;238(1):49–56.PubMedCrossRef

62.

Rebolledo DL, González D, Faundez-Contreras J, Contreras O, Vio CP, Murphy-Ullrich JE, Lipson KE, Brandan E. Denervation-induced skeletal muscle fibrosis is mediated by CTGF/CCN2 independently of TGF-β. Matrix Biol. 2019;82:20–37.PubMedCrossRef

63.

Shimo T, Nakanishi T, Nishida T, Asano M, Sasaki A, Kanyama M, Kuboki T, Matsumura T, Takigawa M. Involvement of CTGF, a hypertrophic chondrocyte-specific gene product, in tumor angiogenesis. Oncol. 2001;61(4):315–22.CrossRef

64.

Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, Rowley DR. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 2005;65(19):8887–95.PubMedCrossRef

65.

Prime SS, Pring M, Davies M, Paterson IC. TGF-beta signal transduction in oro-facial health and non-malignant disease (part I). Crit Rev Oral Biol Med. 2004;15(6):324–36.PubMedCrossRef

Titel: The Role of Increased Connective Tissue Growth Factor in the Pathogenesis of Oral Submucous Fibrosis and its Malignant Transformation—An Immunohistochemical Study
verfasst von: Aakruti Mahendra Shah
Kejal Jain
Rajiv S. Desai
Shivani Bansal
Pankaj Shirsat
Pooja Prasad
Kshitija Bodhankar
Publikationsdatum: 05.02.2021
Verlag: Springer US
Erschienen in: Head and Neck Pathology / Ausgabe 3/2021
Elektronische ISSN: 1936-0568
DOI: https://doi.org/10.1007/s12105-020-01270-9

Springer Medizin

The Role of Increased Connective Tissue Growth Factor in the Pathogenesis of Oral Submucous Fibrosis and its Malignant Transformation—An Immunohistochemical Study

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Disseminated Herpes Simplex Infection Presenting as Acute Supraglottitis in an Adult

Clinicopathological Profile of 80 Cases of Unicystic Ameloblastoma Aided by a Histopathological Comparison Using Modified Philipsen–Reichart Classification and Marx–Stern Classification

Primary and Secondary/ Metastatic Salivary Duct Carcinoma Presenting within the Sinonasal Tract

Molecular and Immunohistochemical Cognizance of HPV16 in Oral Leukoplakia, Oral Squamous Cell Carcinoma and Oropharyngeal Squamous Cell Carcinoma

Palatal Soft Tissue Myxoma in a Patient with Carney Complex

Human Papillomavirus (HPV)-Related Carcinoma of the Oropharynx with Squamous Cell and Adenoid Cystic Carcinoma-Like Features: Report of a Case

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie